We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Clinical Evaluation of human embryonic stem cells (hESCs) induced with directed differentiation to gonadotrope cells to cure vasculogenic impotency and to improve coital frequency in males. An open st
Poster

Clinical Evaluation of human embryonic stem cells (hESCs) induced with directed differentiation to gonadotrope cells to cure vasculogenic impotency and to improve coital frequency in males. An open st

Clinical Evaluation of human embryonic stem cells (hESCs) induced with directed differentiation to gonadotrope cells to cure vasculogenic impotency and to improve coital frequency in males. An open st
Poster

Clinical Evaluation of human embryonic stem cells (hESCs) induced with directed differentiation to gonadotrope cells to cure vasculogenic impotency and to improve coital frequency in males. An open st

This work demonstrates the clinical efficacy, tolerability and safety of patient-syngenic hESC induced with directed differentiation to gonadotrope cells. Hypothalamus transmits gonadotropin releasing factor to pituitary that sets off LH and FSH to Sertoli cell and Seminiferous tubule resulting Leydig cell to produces testosterone. This potential offers a rationale to evaluate hESCs to cure patients with vasculogenic impotency and to improve coital frequency in males.
Advertisement